Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.
Company Details
- Employees
- 38
- Founded
- -
- Address
- 343 Oyster Point Blvd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://neuron23.com
- Keywords
- biotech, precision medicine, immunological diseases, neurological diseases, neurodegenerative diseases, neuroinflammatory diseases, autoimmune diseases, inflammatory diseases, human genetics, data science, Parkinson's disease, Crohn's disease, Ulcerative colitis, psoriasis, IBD, ankylosing spondylitis.
- HQ
- South San Francisco, California
Neuron23 Questions
Neuron23's website is https://neuron23.com
Neuron23's LinkedIn profile is https://www.linkedin.com/company/neuron23-inc
Neuron23 has
38 employees.
View email and phone details for 38
employees at Neuron23.
Neuron23's industry is
Biotechnology Research
Neuron23's top competitors are
Abridge,
Alector,
Bioage Labs,
Denali Therapeutics,
Star Therapeutics,
Neurogene Inc.,
Kenai Therapeutics,
Latigo Biotherapeutics, Inc.,
Allogene Therapeutics,
Neurona Therapeutics.
Neuron23's categories are Biotechnology Research
Neuron23's founding year is 2018
